Pomalidomid/Dexamethason und remissionsabhängig Cyclophosphamid bei Myelom-Rezidiv (#550)
Laufzeit: 01.01.2014 - 31.12.2019
imported
Kurzfassung
Phase II multicenter, open‐label, single arm clinical Study of Pomalidomide and dexamethasonE in RelapSed myeloma Plus rEsponse adapted Cyclophosphamide as a Tailored InnoVativE strategy (PERSPECTIVE)
